Outlook Therapeutics, Inc.

OTLK

$0.63

+0.51%

2026-09-02 16:00:00 EDT+$0.00

Healthcare

Biotechnology

NASDAQ

Active Trading

Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal ...

Price Action of OTLK

$0.63

+0.51%+$0.00

High—

Low—

52W High-75.3%

Rel. vol—

Interval

Range6.5h

Volume—SMA5SMA10

—

Outlook Therapeutics, Inc. is a biopharmaceutical company that has been in advanced stages of clinical development, concentrating on the invention and market introduction of monoclonal antibody treatments for eye conditions. The company's primary drug candidate, ONS-5010 (now marketed as LYTENAVA™, bevacizumab-vikg), is an ophthalmic formulation of bevacizumab that received FDA ...Outlook Therapeutics, Inc. is a biopharmaceutical company that has been in advanced stages of clinical development, concentrating on the invention and market introduction of monoclonal antibody treatments for eye conditions. The company's primary drug candidate, ONS-5010 (now marketed as LYTENAVA™, bevacizumab-vikg), is an ophthalmic formulation of bevacizumab that received FDA approval in July 2026 as the first and only FDA-approved ophthalmic bevacizumab for the treatment of wet age-related macular degeneration (AMD). This approval marked a significant milestone for the company, which had been pursuing this goal for many years. The company's business strategy includes forging strategic collaborations and licensing agreements with partners such as IPCA Laboratories, Laboratorios Liomont, BioLexis Pte. Ltd., and Zhejiang Huahai Pharmaceutical Co., Ltd. Financially, Outlook Therapeutics has faced challenges typical of a clinical-stage biotech, with no significant revenue and ongoing operating losses, as indicated by negative margins and cash flow from operations. The company has funded operations through equity offerings and debt financing. As of the latest data, the company has a market capitalization of about $211 million and a stock price around $1.13. Despite the negative profitability, the FDA approval of LYTENAVA™ provides a pathway to commercial revenue. Key leadership includes CEO Robert Charles Jahr, who was appointed in 2021, and other executives like CFO Lawrence Kenyon. The company is headquartered in Iselin, New Jersey, and employs 17 full-time staff. Looking forward, the company aims to leverage its approved product to capture a portion of the large market for anti-VEGF treatments in retinal diseases, competing with established products like Eylea and Lucentis, while also pursuing additional indications. The long-term success will depend on commercial execution, market acceptance, and competitive dynamics.ExpandCollapse

Founded

2010

Employees

CEO

Robert Charles Jahr

Full Name

Outlook Therapeutics, Inc.

Sector

Healthcare

Industry

Biotechnology

ROE

222.01%

Market Cap

$0.12B

Current Ratio

0.81

WACC

5.85%

ROIC

1142.86%

Contact Information

https://www.outlooktherapeutics.com

609 619 3990

111 S. Wood Avenue, Iselin, NJ 08830

Key Metrics of OTLK

Snapshot

Latest / TTM · 6 periods

Market Cap

$117.12M

ROCE

2230.6%

EV / EBITDA

-2.06x

+1984.3% YoY

FCF Yield

-47.1%

+144.9% YoY

Cash Conversion Cycle

-1094.7d

Current Ratio

0.81

Quick take

TTM —

Current ratio below 1.0

Negative working capital

Financial Highlights of OTLK

Profitability trend

Latest / TTM · 6 periods

Gross Margin

195.6%

Net Margin

5254.8%

P/E Ratio

-0.35x

n/a

Debt / Equity

-1.77

n/a

Current Ratio

0.81

Dividend Yield

0.0%

Understanding

TTM —

Current ratio below 1.0

Interest coverage is weak

Calendar of OTLK

Upcoming

Sep 30, 2026In 26 days
FY2026 · Estimated annual results
Est. EPS $-0.49 · Revenue $2.46M · 1 analysts
Dec 30, 2026
Q1 FY2027 · Estimated results
Est. EPS $-0.06 · Revenue $5.30M · 3 analysts
Mar 30, 2027
Q2 FY2027 · Estimated results
Est. EPS $-0.06 · Revenue $8.58M · 1 analysts
Jun 30, 2027
Q3 FY2027 · Estimated results
Est. EPS $-0.05 · Revenue $10.30M · 1 analysts

Recent history

Aug 18, 2026
Q3 FY2026 · Results reported
EPS $-0.80 · Revenue $9000.00
View filing
May 15, 2026
Q2 FY2026 · Results reported
EPS $-0.17 · Revenue $127439.00
View filing
Dec 31, 2025
Q1 FY2026 · Results reported
EPS $-0.38 · Revenue $-1.21M
Sep 30, 2025
FY2025 · Annual results
EPS $-1.79 · Revenue $1.41M
Jun 30, 2025
Q3 FY2025 · Results reported
EPS $-0.55 · Revenue $1.51M
Mar 31, 2025
Q2 FY2025 · Results reported
EPS $-1.50 · Revenue $0.00

Financial Statements of OTLK

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$1.4M	—	-92.9%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$-62.4M	+17.2%	-356.3%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	+46.5%	—	-417.5%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	-4744.3%	—	-991.2%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	-4416.2%	—	-6361.0%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$-51.8M	+24.7%	-180.9%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	-3666.7%	—	-3877.4%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	-93.8%	-130.5%	-89.1%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	0.38x	-41.1%	+50.3%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$18.6M	-35.5%	+19.6%

Actual vs Estimate

A Sep 30Q Jun 30

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	-1.79 vs -1.80	+0.4%	-0.80 vs -0.08	-900.0%
Revenue Surprise	$1.4M vs $6.7M	-78.9%	$9000 vs $966667	-99.1%

Insider Transactions of OTLK

Acquisitions (A)

Since Jul 21, 2026

Disposals (D)

Since Jul 21, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
Sep 1, 2026	Lundquist Kevin Michael	officer: Chief Financial Officer	Employee Stock Option (Right to Buy)	A	500,000	$0.63
Sep 1, 2026	Lundquist Kevin Michael	—	—	—	0	—
Aug 14, 2026	Jahr Robert Charles	director, officer: Chief Executive Officer	Common Stock	A	151,515	$0.99
Aug 14, 2026	Jahr Robert Charles	director, officer: Chief Executive Officer	Warrants (right to buy)	A	151,515	$1.10
Aug 14, 2026	KENYON LAWRENCE A	director, officer: Chief Financial Officer	Common Stock	A	101,010	$0.99

Earnings Call Transcript of OTLK

1 transcript segments

Q3 2026

Unknown Speaker

Operator: Hello, everyone, and welcome to the Outlook Therapeutics Third Quarter Fiscal Year 2026 Corporate Update Conference Call and Webcast. [Operator Instructions] Note that this webcast is being recorded, and a replay will be made available on the company's website following the end of the event. At this time, I'd like to remind our listeners that remarks made during this webcast may state management's intentions, beliefs, expectations, plans or future projections. These are forward-looking statements and involve risks and uncertainties. As a result, you should not place undue reliance on any forward-looking statements. Some of the factors that could cause actual results to differ materially from those contemplated by such forward-looking statements are discussed in the periodic reports Outlook Therapeutics files with the Securities and Exchange Commission. These documents are available in the Investors section of the company's website and on the Securities and Exchange Commission's website. We encourage you to review these documents carefully. Additionally, certain information contained in the webcast relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the company's own estimates and research. While the adequacy, fairness and accuracy of the completeness of or that any independent source has verified any information obtained from the third-party sources. Joining us on today's call from the Outlook Therapeutics leadership team are Bob Jahr, President and Chief Executive Officer; and Lawrence Kenyon, Executive Vice President and Chief Financial Officer. I would now like to turn the call over to Bob Jahr, President and Chief Executive Officer. Please proceed. Robert Jahr: Thank you, operator, and good morning, everyone. We are entering a defining new chapter for Outlook Therapeutics. Only 3 weeks ago, the FDA approved LYTENAVA as the only FDA-approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the United States. Securing FDA approval is a transformational achievement for Outlook Therapeutics and an important development for the U.S. retina community. It significantly expands the commercial opportunity before us and positions the company to bring LYTENAVA to the world's largest retina market. For over 20 years, bevacizumab has played a central role in the treatment of retinal disease. Retina specialists know the molecule, have extensive experience using it and continue to rely on the repackaged off-label bevacizumab across millions of injections annually. Until now, however, physicians in the United States did not have access to ophthalmic formulation of bevacizumab that adheres with the FDA standards from manufacturing to the practice and developed specifically for administration in the eye. We are now changing that with the approval of LYTENAVA. We are not introducing an unfamiliar molecule or asking physicians to rethink the important role beva plays in …

Leadership Team of OTLK

6 executives

Name	Title	Compensation	Gender	Year Born	Status
Robert Charles Jahr	President, Chief Executive Officer & Director	USD 603,062	Male	1973	Active
Lawrence A. Kenyon	EVP, CFO, Treasurer, Secretary & Director	USD 476,170	Male	1966	Active
Jennifer Kissner	Senior Vice President of Clinical Development & Regulatory Affairs	—	—	—	Active
Jedd Comiskey	Senior Vice President - Head of Europe	—	Male	—	Active
Surendra Sharma	Senior Vice President of Medical Affairs	—	—	—	Active
Joel Prieve	Senior Vice President of Licensing and M&A	—	Male	—	Active

Recent News of OTLK

Zacks Investment Research8/10/2026Neutral

OTLK Up More Than 300% in 3 Months: Here's What You Should Know

Outlook Therapeutics rallies 311.8% in three months as Lytenava's FDA approval boosts optimism ahead of its planned U.S. launch by year-end.

Zacks Investment Research8/6/2026Neutral

Outlook Therapeutics, Inc. (OTLK) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Outlook Therapeutics, Inc. (OTLK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire8/6/2026Neutral

Outlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and Webcast on August 14, 2026

ISELIN, N.J., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that it will report its financial results for the third quarter fiscal year 2026 and will host a corporate update conference call and webcast on Friday, August 14, 2026, at 8:30 AM ET.

Zacks Investment Research8/3/2026Neutral

Outlook Therapeutics to Report Q3 Earnings: What's in the Cards?

OTLK heads into Q3 results with investors watching European Lytenava sales, U.S. launch plans and updates after its landmark FDA approval.

Seeking Alpha7/28/2026Neutral

Outlook: 'Hold' - Caution On LYTENAVA FDA Approval And Cash Needs

Outlook Therapeutics (OTLK) receives both FDA and European approval for LYTENAVA, targeting wet AMD, but faces significant commercialization challenges. I downgrade OTLK to 'Hold' due to acute cash constraints and the urgent need for strategic funding or a partnership to support U.S. launch. LYTENAVA offers a lower-cost, ophthalmic bevacizumab alternative in a competitive $8.5B U.S. anti-VEGF retina market, but market capture remains uncertain.

Historical Employee Count of OTLK

Current

Change

-26.09%

Minimum

Maximum

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Sep 30, 2025	17	10-K	Dec 19, 2025	View
Sep 30, 2024	23	10-K	Dec 27, 2024	View
Sep 30, 2023	24	10-K	Dec 22, 2023	View
Sep 30, 2022	17	10-K	Dec 29, 2022	View
Sep 30, 2021	9	10-K	Dec 23, 2021	View

Related stocksBiotechnology

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

Outlook Therapeutics, Inc.